2023 Research Workshop Presentations Jonathan Noujaim, MD , Assistant Clinical Professor of Medicine, Universite de Montreal (Canada) - “Tyrosine kinase inhibitors in desmoid type fibromatosis - a Canadian multicenter retrospective CanSaRCC study.” Bernd Kasper, MD, PhD , Professor, University of Heidelberg, Mannheim University Medical Center, Mannheim Cancer Center, Sarcoma Unit (Germany) - “Global consensus paper on desmoid tumor management.”
Gerlinde Wernig, MD , Assistant Professor, Department of Pathology, Stanford University School of Medicine - “Studying CD47 blockade as an immunotherapy for desmoid-type fibromatosis.”
Kris Vleminckx, PhD , Full Professor, Department of Biomedical Molecular Biology, Ghent University (Belgium) - “Investigating EZH2 as a druggable mediator of immune cell exclusion in desmoid tumors.”
Jesse Boehm, PhD , Principal Investigator, Koch Institute, MIT - “Progress towards creating a prototype desmoid tumor dependency map.”
Gabe Augdahl , Desmoid Tumor Patient
Cristabelle De Souza, PhD , Postdoctoral Fellow, Cancer Biology, Stanford University - “Activation of c-JUN modulates the transcriptional activity of CD63 serving as a novel target for the treatment of desmoid type fibromatosis.” Paul Huang, PhD , Head, Molecular and Systems Oncology Laboratory Division of Molecular Pathology, Institute of Cancer Research (UK) - “What has proteomics taught us about desmoid tumours?”
Linda Holtzman, MHA, RHIA, CCS, CCS-P, CPC, COC , President, Clarity Coding - “New desmoid tumor ICD-10-CM codes.”
15
Made with FlippingBook Online newsletter maker